Maurizio Cosimo Nacchiero
University of Foggia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maurizio Cosimo Nacchiero.
Clinical Drug Investigation | 2006
Enzo Ierardi; Nicola Della Valle; Maurizio Cosimo Nacchiero; Vincenzo De Francesco; G. Stoppino; C. Panella
We report the case of a patient with refractory ulcerative colitis who developed cholestatic acute liver damage after a single infusion of infliximab. Unusual aspects of this case were the early onset (after the first administration) of liver damage and the absence of antinuclear antibodies, alcohol intake, hepatotoxic drugs and all known viral and metabolic causes of hepatic injury. Moreover, no serological or morphological findings of primary sclerosing cholangitis were observed. The patient’s liver damage resolved spontaneously within 6 weeks. Although a direct relationship between administration of infliximab and onset of acute liver damage could not be definitely established, our case suggests that infliximab may induce direct liver damage, the course of which is similar to acute cholestatic hepatitis and resolves following withdrawal of the drug.
Journal of Gastroenterology and Hepatology | 2018
Antonio Facciorusso; Valentina Del Prete; Antonio Turco; Rosario Vincenzo Buccino; Maurizio Cosimo Nacchiero; Nicola Muscatiello
Observational studies showed significant liver stiffness regression after sustained virological response, but long‐term effects of antiviral therapy are still unknown. The aim of this study was to assess the magnitude of change in stiffness up to 5 years after therapy in hepatitis C patients undergoing antiviral treatment.
Current Drug Safety | 2011
Antonio Facciorusso; Maurizio Cosimo Nacchiero; Rosa Rosania; G. Laonigro; Nunzio Longo; C. Panella; Enzo Ierardi
Albumin constitutes approximately one half of the proteins in the plasma and plays a pivotal role in modulating the distribution of fluid between body compartments. Hence it is commonly employed in cirrhotic patients in association with diuretics for the treatment of ascites. Nevertheless, its usefulness is controversial in this condition and well-stated only in some circumstances. The item of safety of the drug appears to be convincing due to the accurate cautions in the course of its preparation. Side effects are described in literature only as sporadic events. Indeed, albumin administration is effective to prevent the circulatory dysfunctions after large-volume paracentesis and renal failure and after Spontaneous Bacterial Peritonitis (SBP). Finally albumin represents, associated with vasoconstrictors, the therapeutic gold standard for the hepatorenal-syndrome (HRS). Physiopathological bases of the therapeutic use of albumin in hepatic cirrhosis consist in both hypoalbuminemia and portal hypertension consequences. In fact, cirrhotic patient with ascites, in spite of hydrosaline retention, shows an effective hypovolemia with peripheral arterial vasodilatation and increase in heart rate. Therefore the effectiveness of albumin administration in the treatment of ascites is due to its plasma volume expander property as well as its efficacy in restoring plasmatic oncotic pressure. Trials are in progress in order to define the effectiveness of the prolonged home-administration of human albumin in the treatment and prevention of ascites. Finally, it has been recently demonstrated that the binding, transport and detoxification capacities of human albumin are severely reduced in cirrhotics and this impairment correlates with the degree of liver failure. Therefore, the next challenge will be to determine whether the alterations of non-oncotic properties of albumin are able to forecast mortality in cirrhotics with ascites and exogenous albumin chronic administration will be effective in predicting and preventing such alterations.
Journal of Gastroenterology and Hepatology | 2018
Antonio Facciorusso; Valentina Del Prete; Vincenzo Buccino; Nicola Della Valle; Maurizio Cosimo Nacchiero; Nicola Muscatiello
Full‐spectrum endoscopy represents a new endoscopic platform allowing a panoramic 330 degree view of the colon, but evidence of its superiority over standard colonoscopy is still lacking. Our study is the first meta‐analysis comparing the efficacy of full‐spectrum endoscopy with standard colonoscopy.
Clinical Gastroenterology and Hepatology | 2017
Antonio Facciorusso; Valentina Del Prete; Rosario Vincenzo Buccino; Nicola Della Valle; Maurizio Cosimo Nacchiero; Fabio Monica; Renato Cannizzaro; Nicola Muscatiello
BACKGROUND & AIMS Several add‐on devices have been developed to increase rates of colon adenoma detection (ADR). We assessed their overall and comparative efficacy, and estimated absolute magnitude of benefit through a network meta‐analysis. METHODS We searched the PubMed/Medline and Embase database through March 2017 and identified 25 randomized controlled trials (comprising 16,103 patients) that compared the efficacy of add‐on devices (cap; Endocuff; Arc Medical Design Ltd, Leeds, UK, and Endorings; Us Endoscopy, Mentor, OH) with each other or with standard colonoscopy. The primary outcome was ADR; secondary outcomes included rate of polyp detection, and rate of and time to cecal intubation. We performed pairwise and network meta‐analyses, and appraised quality of evidence using Grading of Recommendations Assessment, Development and Evaluation. We estimated the magnitude of increase in ADR by low‐performing endoscopists (baseline ADR, 10%) and high‐performing endoscopists (baseline ADR, 40%) with use of these devices. RESULTS Overall, distal attachment devices increased ADR compared with standard colonoscopy (relative risk [RR], 1.13; 95% CI, 1.03–1.23; low‐quality evidence), with potential absolute increases in ADR to 11.3% for low‐performing endoscopists and to 45.2% for high‐performing endoscopists. In a comparative evaluation, we found low‐quality evidence that Endocuff increases ADR compared with standard colonoscopy (RR, 1.21; 95% CI, 1.03–1.41), with anticipated increases in ADR to 12% for low‐performing endoscopists and to 48% for high‐performing endoscopists. We found very low quality evidence to support the use of Endorings (RR, 1.70; 95% CI, 0.86–3.36) or caps (RR, 1.07; 95% CI, 0.96–1.19) vs standard colonoscopy for increasing ADR. The benefit of one distal attachment device over another was uncertain due to very low quality evidence. CONCLUSIONS Based on network meta‐analysis, we anticipate only modest improvement in ADRs with use of distal attachment devices, especially in low‐performing endoscopists.
Alimentary Pharmacology & Therapeutics | 2003
Enzo Ierardi; Nicola Muscatiello; Maurizio Cosimo Nacchiero; M. Gentile; M. Margiotta; S. Marangi; V. De Francesco; Ruggiero Francavilla; Michele Barone; D. Faleo; C. Panella; Antonio Francavilla; Rosario Cuomo
Background : Recently, biliary sludge has been strongly correlated with ‘idiopathic pancreatitis’. It is often diagnosed by trans‐abdominal ultrasonography, despite the low sensitivity of this investigation. New scanners, using second harmonic imaging, may improve the quality of the echographic picture.
Endoscopy | 2008
Nicola Muscatiello; Maurizio Cosimo Nacchiero; N. Della Valle; F. Di Terlizzi; G. Verderosa; A. Salcuni; Luca Macarini; M. Cignarelli; M. Castriota; V. D'Agnessa; Enzo Ierardi
Inflammatory Bowel Diseases | 2006
Enzo Ierardi; Nicola Della Valle; Maurizio Cosimo Nacchiero; Vincenzo De Francesco; G. Stoppino; C. Panella
European Journal of Radiology Extra | 2004
Nicola Crucinio; Maurizio Cosimo Nacchiero; C. Panella; Enzo Ierardi
Archive | 2010
Maurizio Cosimo Nacchiero; Giovanna Verderosa; Nicola Muscatiello; Nicola Della Valle; Francesco Diterlizzi; Giovanni Di Gioia; Rocco Melino; C. Panella; Enzo Ierardi